LMAT

Business Context and Reporting Period

Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. The company operates in a single segment with principal product lines including thoracic and abdominal stent grafts, anastomotic clips, and vascular grafts. The company is classified as a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 20% year-over-year, driven by newly acquired product lines (Biomateriali, Vascular Architects), strong performance in the open vascular category, and a weaker U.S. dollar.
• Margin Compression: Gross margin decreased from 74.6% to 71.7%. This was primarily due to the inclusion of lower-margin sales from the Biomateriali subsidiary and increased European sales where average selling prices are lower.
• Operating Expenses: Total operating expenses rose significantly due to:
  • Restructuring Charges: Increased from $6,000 to $633,000, driven by severance costs for 32 employees (13% of workforce) and termination costs for European distributors.
  • Impairment Charge: A $435,000 charge was recorded for the write-down of intangible assets after a Biomateriali customer ceased purchasing certain product lines.
  • Sales & Marketing: Increased 21% due to a larger sales force and start-up costs in France and Italy.
• Liquidity: Cash and cash equivalents decreased by $1.2 million during the quarter. Total liquid assets (cash + marketable securities) stood at $17.8 million.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects cash balances to decrease as the company funds operations, acquisitions, and deferred payments. They believe current liquidity is sufficient for at least the next 12 months but may require additional financing for future acquisitions.
• Unusual Items:
  • Restructuring: $633,000 in charges related to workforce reduction and distributor terminations.
  • Impairment: $435,000 charge related to Biomateriali customer loss.
  • Indemnity Claim: The company notified sellers of Biomateriali of an indemnity claim for approximately $0.5 million regarding undisclosed customer relationship issues and has ceased certain post-closing payments pending resolution.
• Risks and Contingencies:
  • Internal Controls: The company identified a material weakness in internal control over financial reporting regarding accruals and reconciliation procedures. As of March 31, 2008, disclosure controls and procedures were deemed not effective. Remediation efforts are underway.
  • Foreign Currency: Approximately 46% of sales are denominated in foreign currencies, exposing the company to exchange rate fluctuations.
  • Contractual Obligations: Significant purchase commitments for inventory ($6.75 million total) and potential contingent payments for Biomateriali (up to $2.2 million).

Investor Verification Checklist

• Internal Control Remediation: Verify the progress of hiring new finance personnel and implementing new reconciliation procedures to address the material weakness in financial reporting.
• Biomateriali Integration: Monitor the impact of the Biomateriali acquisition on gross margins and the resolution of the $0.5 million indemnity claim.
• Liquidity Runway: Assess the burn rate given the $4.3 million net cash used in operating activities and the company's reliance on existing cash reserves for future acquisitions.
• Restructuring Costs: Track the actual cash outflow for the $633,000 in restructuring charges to ensure they align with the estimated timeline.
• Customer Concentration: Evaluate the risk associated with the loss of the Biomateriali customer that triggered the impairment charge and whether similar risks exist for other product lines.